rezpegaldesleukin

New clinical data for rezpegaldesleukin, an immune-regulating drug candidate, show long-term durability and disease improvement in patients with alopecia areata and atopic dermatitis. The findings are being presented at the EADV Congress 2026, Europe's major dermatology meeting. The data support the treatment's potential for these chronic inflammatory skin conditions, where maintaining improvement over time remains a key challenge for patients and physicians.

New biomarker data on rezpegaldesleukin were presented in a late-breaking oral presentation at the EADV Congress 2026. The findings show early molecular responses to the drug across multiple immune pathways that are dysregulated in patients with atopic dermatitis. The data suggest the therapy, an immune-regulating treatment, is being positioned as a potential option for the inflammatory skin condition, and the presentation is drawing attention from the dermatology community.